Peter Hillmen Selected Research

Peter Hillmen Research Topics

Disease

76	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 01/2002
26	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 09/2022 - 05/2002
24	Hemolysis 09/2022 - 01/2002
19	Neoplasms (Cancer) 11/2021 - 01/2002
15	Residual Neoplasm 11/2021 - 03/2004
14	Disease Progression 01/2022 - 03/2004
14	Infections 11/2021 - 01/2002
13	Fatigue 09/2022 - 09/2006
9	Diarrhea 01/2021 - 07/2014
8	Thrombosis (Thrombus) 01/2020 - 11/2003
8	Neutropenia 01/2019 - 05/2015
6	Atrial Fibrillation 11/2021 - 03/2015
6	Hemorrhage 01/2021 - 11/2003
6	Lymphocytosis 01/2020 - 12/2007
5	Anemia 09/2022 - 04/2005
5	Hypertension (High Blood Pressure) 12/2019 - 05/2010
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2018 - 04/2005
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 08/2003
4	Chronic Disease (Chronic Diseases) 01/2021 - 09/2006
4	Cough 01/2019 - 07/2014
4	Nausea 12/2018 - 12/2007
4	Pulmonary Hypertension 07/2013 - 04/2005
3	Abdominal Pain (Pain, Abdominal) 09/2022 - 05/2007
3	Hemoglobinuria 09/2022 - 02/2004
3	Leukemia 12/2020 - 02/2006
3	Fever (Fevers) 12/2018 - 07/2014
3	Cytopenia 12/2013 - 01/2002
2	Deglutition Disorders (Dysphagia) 09/2022 - 05/2007
2	Erectile Dysfunction 09/2022 - 05/2007
2	Headache (Headaches) 01/2021 - 01/2019
2	Aplastic Anemia (Anemia, Hypoplastic) 11/2019 - 01/2018
2	B-Cell Lymphoma (Lymphoma, B Cell) 05/2019 - 01/2018
2	Pneumonia (Pneumonitis) 01/2019 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 12/2018 - 03/2002
2	Tumor Lysis Syndrome 12/2018 - 03/2018
2	Febrile Neutropenia 03/2018 - 01/2017
2	Thrombocytopenia (Thrombopenia) 01/2017 - 02/2008
2	Lymphadenopathy 01/2017 - 04/2010
2	Vomiting 12/2015 - 12/2007
2	Lymphoid Leukemia 07/2014 - 01/2004
2	Chronic Renal Insufficiency 07/2013 - 08/2010
1	Dyspnea (Shortness of Breath) 09/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021
1	Atrial Flutter (Flutter, Atrial) 11/2021
1	Injection Site Reaction 01/2021
1	COVID-19 10/2020
1	Spontaneous Remission 01/2020

Drug/Important Bio-Agent (IBA)

35	ibrutinibIBA 01/2022 - 07/2014
26	eculizumab FDA Link 09/2022 - 02/2004
18	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2016
16	Rituximab (Mabthera)FDA Link 01/2022 - 02/2004
13	Complement System Proteins (Complement)IBA 01/2021 - 01/2002
13	Alemtuzumab (Campath)FDA Link 01/2017 - 01/2002
12	fludarabineIBA 01/2022 - 03/2002
10	ofatumumab FDA Link 01/2020 - 04/2010
9	Chlorambucil (Leukeran)FDA Link 01/2022 - 12/2007
9	acalabrutinibIBA 01/2022 - 01/2016
8	idelalisibIBA 01/2021 - 03/2014
7	venetoclaxIBA 12/2020 - 01/2018
5	Bendamustine Hydrochloride FDA Link 01/2022 - 01/2017
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 04/2005
5	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 08/2021 - 05/2002
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2013 - 10/2005
4	Biological ProductsIBA 01/2020 - 01/2004
4	Proteins (Proteins, Gene)FDA Link 03/2018 - 01/2002
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2012 - 04/2005
4	Monoclonal AntibodiesIBA 06/2011 - 03/2002
4	Complement Inactivating AgentsIBA 08/2010 - 09/2006
3	zanubrutinibIBA 01/2022 - 04/2020
3	serum P-component (CIt)IBA 10/2021 - 11/2018
3	GPI-Linked ProteinsIBA 08/2021 - 01/2004
3	Pharmaceutical PreparationsIBA 01/2021 - 10/2016
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 04/2005
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2019 - 12/2007
2	TESIBA 09/2022 - 07/2013
2	Transaminases (Aminotransferases)IBA 12/2020 - 01/2019
2	duvelisibIBA 01/2020 - 12/2018
2	Biomarkers (Surrogate Marker)IBA 05/2019 - 08/2012
2	AntibodiesIBA 03/2016 - 01/2004
2	Lenalidomide (CC 5013)FDA Link 01/2016 - 03/2012
2	pro-brain natriuretic peptide (1-76)IBA 08/2012 - 05/2010
2	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2012 - 05/2010
2	Warfarin (Coumadin)FDA LinkGeneric 06/2011 - 11/2003
2	Alkylating AgentsIBA 09/2007 - 05/2002
2	purineIBA 01/2004 - 08/2003
1	Indicators and Reagents (Reagents)IBA 11/2021
1	Peptides (Polypeptides)IBA 01/2021
1	ravulizumabIBA 01/2021
1	pegcetacoplanIBA 01/2021
1	forodesineIBA 12/2020
1	deoxyguanosine triphosphate (dGTP)IBA 12/2020
1	FibrinIBA 01/2020
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 01/2020
1	tirabrutinibIBA 01/2020
1	Immunoglobulin Variable RegionIBA 01/2020

Therapy/Procedure

46	Therapeutics 01/2022 - 03/2002
8	Drug Therapy (Chemotherapy) 11/2019 - 03/2002
3	Aftercare (After-Treatment) 01/2017 - 05/2002
2	Blood Transfusion (Blood Transfusions) 12/2013 - 01/2009
1	Precision Medicine 12/2020